What sector does StemCell Institute belong to?

StemCell Institute operates in the Industrials sector, specifically the Services industry, and is listed on the US markets.

What is the current share price of 7096?

As of the latest available quote, 7096 traded at ¥748.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of 7096?

StemCell Institute has a price-to-earnings (P/E) ratio of about 48.54. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of 7096?

The market capitalisation of StemCell Institute is approximately ¥7.55B.

Is StemCell Institute profitable?

For its latest reported financial year, StemCell Institute recorded a net profit margin of about 5.55%.

Does 7096 pay a dividend?

StemCell Institute does not currently show a dividend yield in our data.

What is the return on equity (ROE) of 7096?

StemCell Institute has a return on equity (ROE) of about 5.81%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of 7096?

Over the past 52 weeks, 7096 has traded between a low of ¥627.00 and a high of ¥976.00.

StemCell Institute

7096 TSE Industrials Services

TSE Growth

¥748.00

-0.27%

Delayed · cached 15 min

Fair value analysis

7096

StemCell Institute

¥748.00

Close used for this calculation

¥300.51Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

26/100

Profitability11/25

Returns3/25

Balance Sheet1/25

Efficiency11/25

Growth6/25

Weak

Quality radar

Consensus fair value

¥300.51

Above FV

▼ -59.8% against the close used

Model range ¥60.37 – ¥426.27

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥60.37Fair value¥300.51Bull¥426.27

FairClose

52-week traded range

52W low ¥637.0052W high ¥956.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

StemCell Institute closed at ¥748.00, 148.9% above the consensus fair value of ¥300.51 drawn from 9 valuation models.

Financial DNA score 26/100 — Weak. P/E of 48.5x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

¥228.68

-69.4%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=3.9%, r=10%, tg=3%, n=10yr

Graham Number

¥304.10

-59.3%

√(22.5 × EPS × BVPS)

EPS=15.44, BVPS=266.19 · outside Graham range (P/E 48.5, P/B 2.8) — asset-light, treat as a rough floor

P/E Fair Value

¥308.80

-58.7%

EPS × 20x (sector P/E)

EPS=15.44, Sector P/E=20x

Peter Lynch (PEG)

¥60.37

-91.9%

EPS × Growth% (PEG = 1 is fair)

EPS=15.44, g=3.9%

EV/EBITDA

¥388.16

-48.1%

(EBITDA × 12x − Net Debt) ÷ Shares

EBITDA=359.41M

Dividend Discount (DDM)

¥426.27

-43.0%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=24.98, r=10%, g=3.9%

Book Value (P/B)

¥83.05

-88.9%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=266.19, ROE=5.8%, g=3.9%, r=10%

Reverse DCF

¥748.00

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 19.1% | Historical: 3.9%

Margin of Safety

¥210.39

-71.9%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=280.53, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer